Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Precision biomarker sits at the center of this dementia and brain health question.
Researchers have discovered a precision biomarker called DOPA decarboxylase (DDC) in cerebrospinal fluid that can identify Parkinson’s disease and Lewy body dementia with unprecedented accuracy. The discovery, published in Nature Medicine in March 2026, shows that concentrations of this protein are up to 2.5 times higher in patients with these conditions compared to healthy controls, providing an objective diagnostic tool that can prevent the costly misdiagnosis that currently plagues these diseases. This breakthrough, led by Dr. Katharina Bolsewig and Prof.
Charlotte Teunissen at the Laboratory of Neurochemistry at UMC Amsterdam, addresses one of the most pressing challenges in neurological medicine: distinguishing Lewy body dementia from Alzheimer’s disease and other conditions that present with similar symptoms. The significance of this discovery lies not just in what it measures, but in what it solves. Dementia with Lewy bodies is frequently misdiagnosed as Alzheimer’s disease, causing patients to receive ineffective or even harmful treatments for years. With DDC as a biomarker, clinicians now have an objective measure that can guide diagnosis earlier and more accurately, potentially changing treatment trajectories for thousands of patients. This article explores what the biomarker is, how it works, why it matters for diagnosis, and what it means for patients and healthcare providers moving forward.
Table of Contents
- How Does the DOPA Decarboxylase Biomarker Identify Lewy Body Disorders?
- The Diagnostic Challenge That DDC Solves
- The Research Behind the Discovery
- How Will the DDC Biomarker Be Used in Clinical Practice?
- Limitations and Future Validation Needs
- How the DDC Biomarker Compares to Other Diagnostic Approaches
- What This Discovery Means for Dementia Research and Patient Care
- Conclusion
- Frequently Asked Questions
How Does the DOPA Decarboxylase Biomarker Identify Lewy Body Disorders?
DOPA decarboxylase is an enzyme that plays a crucial role in dopamine production in the brain. When measured in cerebrospinal fluid—the fluid that bathes the brain and spinal cord—its concentration becomes a measurable indicator of neurological dysfunction specific to Lewy body disorders. The research found that patients with Parkinson’s disease and Lewy body dementia have significantly elevated levels of this protein compared to healthy controls, creating a clear biological distinction that can be detected through laboratory analysis. The mechanism behind this elevation relates to how Lewy body disorders affect dopamine-producing neurons. In both Parkinson’s disease and Lewy body dementia, alpha-synuclein proteins accumulate and damage the very cells responsible for producing dopamine.
This cellular damage leads to higher concentrations of DDC appearing in cerebrospinal fluid, essentially a biological signal that these specific neurons are under stress. What makes this biomarker particularly valuable is its specificity: it distinguishes Lewy body disorders from Alzheimer’s disease and other neurodegenerative conditions that may look similar clinically but have entirely different underlying pathology. A concrete example: A 72-year-old patient presents with cognitive decline, hallucinations, and movement problems. These symptoms overlap with both Lewy body dementia and Alzheimer’s disease. With behavioral assessment alone, clinicians might misclassify the condition. However, a cerebrospinal fluid test measuring DDC levels would show the 2.5-fold elevation characteristic of Lewy body dementia, allowing the doctor to recommend appropriate treatments rather than those designed for Alzheimer’s—a critical distinction that affects everything from medication choices to patient outcomes.
The Diagnostic Challenge That DDC Solves
lewy body dementia remains one of the most frequently misdiagnosed neurological conditions. Because it shares cognitive decline with Alzheimer’s disease and movement symptoms with Parkinson’s disease, patients often receive a diagnosis that is only partially correct, or sometimes entirely incorrect. This misdiagnosis leads to treatment with medications that may worsen symptoms—for example, antipsychotics prescribed for behavioral symptoms can be catastrophic in Lewy body dementia, where they can trigger neuroleptic sensitivity and life-threatening complications. The confusion is understandable: all three conditions involve cognitive decline, and their symptoms can overlap significantly. However, the underlying biology is distinctly different. Lewy body dementia is characterized by alpha-synuclein deposits, while Alzheimer’s disease involves amyloid-beta and tau tangles.
These different pathologies require different treatment approaches. Before the DDC biomarker, clinicians relied heavily on clinical presentation and sometimes imaging, but these methods were imperfect. A diagnostic test that measures DDC in cerebrospinal fluid provides the biological certainty that clinical assessment alone cannot offer. However, it’s important to note that the DDC biomarker is not a replacement for clinical judgment but rather a supplement to it. Doctors still need to evaluate symptoms, medical history, and imaging findings. The biomarker becomes most valuable when clinical presentation is ambiguous—when a patient could plausibly have Lewy body dementia, Alzheimer’s disease, or another condition. In these situations, the objective DDC measurement can provide the clarity needed to guide treatment decisions with confidence.
The Research Behind the Discovery
The discovery of DDC as a Lewy body biomarker emerged from rigorous research conducted at the Laboratory of Neurochemistry at UMC Amsterdam, in collaboration with researchers from VUB and UZ Brussel. Dr. Sebastiaan Engelborghs and his colleagues conducted extensive analysis of cerebrospinal fluid samples from patients with Parkinson’s disease, Lewy body dementia, Alzheimer’s disease, and healthy controls. The study quantified the concentration of DOPA decarboxylase in each group, revealing the consistent elevation in Lewy body disorders that could serve as a diagnostic marker. The research process involved collecting cerebrospinal fluid through lumbar puncture—a procedure where fluid is withdrawn from around the spine—from hundreds of participants across different diagnostic groups.
Researchers then used sophisticated biochemical techniques to measure DDC concentrations with precision. The findings were so clear and consistent that the results warranted publication in Nature Medicine, one of the top-tier medical journals, signifying the quality and importance of the work. This discovery represents years of foundational research in biomarker identification. Scientists didn’t randomly choose DDC; rather, they built on existing knowledge that dopamine system dysfunction is central to Lewy body disorders, and they systematically tested various proteins involved in dopamine production and metabolism. When DDC showed the most consistent and significant differences between diagnostic groups, it emerged as a candidate biomarker worthy of detailed investigation and validation.
How Will the DDC Biomarker Be Used in Clinical Practice?
In practical terms, the DDC biomarker will primarily be used as a diagnostic tool through cerebrospinal fluid testing. Patients suspected of having Lewy body dementia can undergo a lumbar puncture, a relatively low-risk procedure performed by neurologists or specialists, to obtain cerebrospinal fluid for analysis. The DDC levels in this fluid would then be measured in a laboratory and compared to established reference ranges that distinguish healthy controls from Lewy body disorder patients. If DDC is elevated at the 2.5-fold threshold, it supports a diagnosis of Parkinson’s disease or Lewy body dementia. The clinical workflow will likely evolve such that when patients present with ambiguous symptoms—cognitive decline with movement problems, or cognitive decline with hallucinations—neurologists can order a cerebrospinal fluid biomarker panel that includes DDC along with other established biomarkers like phosphorylated tau and amyloid-beta.
This multimarker approach allows simultaneous differentiation of Lewy body disorders from Alzheimer’s disease and can sometimes even identify patients who have mixed pathology (both Lewy bodies and amyloid plaques). One important practical consideration: cerebrospinal fluid testing requires a lumbar puncture, which is invasive compared to blood tests. This means DDC testing won’t replace clinical assessment but will be reserved for situations where diagnosis is genuinely uncertain and the result would change treatment decisions. As research progresses, scientists may eventually develop blood-based biomarkers that reflect DDC or related dopamine system dysfunction, which would make testing more accessible. For now, the lumbar puncture requirement means this biomarker will have the greatest impact in specialized neurology clinics and research settings where such procedures are routine.
Limitations and Future Validation Needs
While the DDC biomarker represents a significant advance, important limitations exist. The initial studies, though rigorous, involved relatively defined patient populations in research settings. Before DDC testing becomes routine in all clinical settings, the biomarker needs validation in diverse populations—different ages, ethnic backgrounds, and comorbidities—to ensure the 2.5-fold elevation threshold holds consistently across real-world patients. A patient presenting to a rural clinic might have different baseline CSF chemistry than the Amsterdam research cohort, potentially affecting interpretation. Additionally, the biomarker measures biological dysfunction but doesn’t directly tell clinicians about disease stage, prognosis, or treatment response.
Two patients with the same elevated DDC levels might have very different disease progression. The biomarker answers the question “Does this patient have a Lewy body disorder?” but not “How quickly will this patient decline?” or “Will this medication help?” Clinicians will still need to combine the biomarker result with clinical assessment, imaging, and the patient’s individual history to make comprehensive treatment decisions. Another limitation worth acknowledging: the research was conducted primarily in Europe at specialized medical centers. The findings need replication across different geographic regions and in diverse healthcare settings before confident recommendations can be made for universal clinical implementation. Furthermore, some patients may have contraindications to lumbar puncture—those on anticoagulants, with spinal pathology, or with other conditions—limiting who can actually benefit from this diagnostic test in the near term.
How the DDC Biomarker Compares to Other Diagnostic Approaches
Currently, diagnosis of Lewy body dementia and Parkinson’s disease relies on clinical criteria developed by expert consensus, sometimes supplemented by imaging like DaT scans that visualize dopamine system dysfunction, or other cerebrospinal fluid biomarkers. The DDC test offers a more direct biological measurement compared to imaging—it measures the protein itself rather than indirect effects of neuronal damage. Compared to clinical diagnosis alone, which can be inaccurate, the DDC biomarker provides objective data. When compared to other cerebrospinal fluid biomarkers like phosphorylated tau and amyloid-beta, which are useful for Alzheimer’s diagnosis, the DDC biomarker fills a gap. Those traditional biomarkers reflect amyloid and tau pathology; they don’t effectively distinguish Lewy body disorders.
DDC is specifically elevated in Lewy body conditions, making it complementary to existing tests rather than a replacement. In an ideal future diagnostic workflow, a cerebrospinal fluid panel would include measurements of amyloid-beta, tau variants, and DDC, allowing simultaneous assessment of all three major dementia pathologies. One specific example of this complementary value: a patient with cognitive decline and mild movement problems could have early Alzheimer’s disease, Lewy body dementia, or both. A traditional tau and amyloid panel might show some abnormalities but not clearly distinguish between Alzheimer’s and Lewy pathology. Adding DDC measurement to that same panel would reveal whether Lewy body pathology is present, clarifying the diagnosis and guiding treatment accordingly.
What This Discovery Means for Dementia Research and Patient Care
The DDC biomarker discovery illustrates a crucial shift in dementia diagnosis: moving from purely clinical assessment toward biologically grounded diagnosis. This aligns with the broader field recognizing that conditions with overlapping symptoms often have distinct molecular causes requiring distinct treatments. As more biomarkers are discovered and validated, the future of dementia care will increasingly involve personalized diagnostic panels that identify the specific pathology each patient carries.
This discovery also has implications for clinical trials and drug development. Pharmaceutical companies developing treatments for Parkinson’s disease or Lewy body dementia can now recruit patients with greater biological certainty, and can use DDC as an outcome measure to assess whether their drugs modify the underlying pathology. This could accelerate drug development by making it easier to identify truly effective treatments. Furthermore, as the field better understands which patients have Lewy body pathology, researchers can develop interventions tailored to the specific mechanisms of alpha-synuclein dysfunction, potentially leading to disease-modifying treatments rather than just symptom management.
Conclusion
The discovery of DOPA decarboxylase as a precision biomarker for Parkinson’s disease and Lewy body dementia represents a major step forward in addressing diagnostic confusion that has cost patients years of inappropriate treatment. With DDC levels up to 2.5 times higher in affected patients compared to healthy controls, clinicians now have an objective biological measure to distinguish Lewy body disorders from Alzheimer’s disease and other conditions. This breakthrough, published in Nature Medicine by an international research team, transforms what has been largely a clinical diagnosis into one informed by measurable biochemistry.
For patients and families, this means better diagnostic accuracy, more appropriate treatment choices, and potentially earlier intervention when diagnosis can be made with confidence. While cerebrospinal fluid testing is not without limitations, and while the biomarker is best used alongside clinical judgment rather than as a standalone diagnostic tool, the availability of a specific, validated biomarker for Lewy body disorders marks a turning point in dementia diagnosis. As research validates DDC across diverse populations and as blood-based versions may eventually be developed, this discovery promises to reduce the diagnostic delays and treatment errors that have long complicated care for patients with these conditions.
Frequently Asked Questions
What exactly is DOPA decarboxylase and why is it elevated in Lewy body dementia?
DOPA decarboxylase is an enzyme crucial for dopamine production in the brain. In Lewy body dementia and Parkinson’s disease, alpha-synuclein proteins accumulate and damage dopamine-producing neurons. This cellular damage causes higher concentrations of DDC to appear in cerebrospinal fluid, where it can be measured as a biomarker of the disease process.
Will I need a lumbar puncture to get tested for this biomarker?
Currently, yes—DDC testing requires cerebrospinal fluid obtained through lumbar puncture. This is a relatively safe procedure performed by trained specialists, but it is more invasive than a blood test. Researchers are exploring whether blood-based versions of this biomarker might be developed in the future, which would make testing more accessible.
Can the DDC biomarker tell me how fast my disease will progress?
No. The biomarker indicates whether Lewy body pathology is present and helps confirm diagnosis, but it doesn’t predict disease progression rate or individual prognosis. Those depend on many factors including age, specific symptoms, other health conditions, and individual variation in disease biology.
How does this biomarker help if I’ve already been diagnosed?
If diagnosis is already confirmed clinically, the biomarker’s primary value is confirming that diagnosis, ensuring treatment is appropriate. In patients with mixed pathology or uncertain diagnosis, the biomarker becomes even more valuable. It also enables participation in research studies that require biologically confirmed diagnoses.
Is this biomarker available at all hospitals?
Not yet. Currently, DDC testing is likely available primarily at specialized neurology centers and research institutions. Broader clinical availability will develop as the test is validated across diverse populations and as more laboratories develop the capability to measure it.
Can I get a blood test for this biomarker instead of a lumbar puncture?
Not currently. The established research measures DDC in cerebrospinal fluid. However, this is an active area of research—scientists are working to develop blood-based versions that might eventually become available as a more convenient alternative.
You Might Also Like
- The Precision Biomarker for Parkinson’s and Lewy Body Dementia That Was Just Discovered
- How Lewy Body Dementia Differs From Alzheimer’s and Why Getting the Right Diagnosis Matters
- How Lewy Body Dementia Differs From Alzheimer’s and Why Getting the Right Diagnosis Matters
For more, see Alzheimer’s Association — caregiving.
